Isotretinoin Drugs Global Market Report 2024

The isotretinoin drugs market size has grown strongly in recent years. It will grow from $1.22 billion in 2023 to $1.29 billion in 2024 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to several factors, including the prevalence of severe acne, the effectiveness of isotretinoin, marketing and awareness campaigns, regulatory approvals, and an increase in dermatology visits.

The isotretinoin drugs market size is expected to see strong growth in the next few years. It will grow to $1.6 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to growing awareness and trends in skincare, expansion into emerging markets, an increasing incidence of acne, an aging population, and a heightened focus on mental health and well-being. Major trends expected during this period include advancements in research and development, technological innovations, innovations in generic drugs, improved formulations, and advances in dermatology.

The growth in skin cancer cases is expected to drive the expansion of the isotretinoin drugs market in the future. Skin cancer results from the uncontrolled growth of abnormal skin cells, often caused by prolonged exposure to ultraviolet (UV) radiation from the sun or tanning beds. The increasing incidence of skin cancer can be attributed to greater UV radiation exposure, depletion of the ozone layer, and lifestyle changes leading to more outdoor activities without sufficient sun protection. Isotretinoin drugs are used to prevent and treat certain types of skin cancer by reducing the proliferation of abnormal skin cells. For example, the American Cancer Society projects that there will be 108,270 reported cases of skin cancer in January 2024, representing a 3.2% increase from the 104,930 cases reported in 2023. Hence, the rising prevalence of skin cancer is set to boost the isotretinoin drugs market.

Key players in the isotretinoin drugs market are concentrating on advancing formulations such as generic capsules to improve treatment options and make them more accessible to patients. Generic capsules are unbranded versions that offer the same efficacy as branded isotretinoin but at a lower cost. For instance, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, launched the first generic version of Absorica (isotretinoin) capsules in April 2021. These capsules are designed for treating severe recalcitrant nodular acne in non-pregnant patients aged 12 and above who have multiple inflammatory nodules with diameters of 5 mm or more and have not responded to conventional acne therapies, including antibiotics.

In January 2024, CHEPLAPHARM Arzneimittel GmbH, a Germany-based pharmaceutical company, acquired Roaccutane from F. Hoffmann-La Roche Ltd. for an undisclosed sum. This acquisition bolsters CHEPLAPHARM Group's dermatological portfolio by securing global rights to Roaccutane, a well-established retinoid medication used to treat severe acne and as a therapeutic option worldwide. F. Hoffmann-La Roche Ltd. is a Switzerland-based healthcare company that manufactures isotretinoin drugs such as Roaccutane.

Major companies operating in the isotretinoin drugs market are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Viatris Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Hetero Drugs Ltd., Sun Pharmaceuticals Industries Limited, Intas Pharmaceuticals Ltd., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Amneal Pharmaceuticals LLC, Lupin Pharmaceuticals Inc, Zydus Lifesciences Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd, Almirall LLC, Alembic Pharmaceuticals Ltd, Ajanta Pharma Ltd, Strides Pharma Science Limited, Wockhardt Ltd., Douglas Pharmaceuticals Limited, Chongqing Huapont Pharm Co. Ltd., Cipher Pharmaceuticals Inc., Vidhyasha Pharmaceuticals.

North America was the largest region in the isotretinoin drugs market in 2023. The regions covered in the isotretinoin drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the isotretinoin drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Isotretinoin is a potent medication derived from vitamin A, primarily used to treat severe acne, often leading to significant improvement in skin conditions. It works by reducing oil production and promoting skin renewal, resulting in clearer and healthier skin for many individuals. Typically prescribed when other treatments have failed, it requires strict medical supervision and careful consideration of potential risks and benefits.

The main types of isotretinoin drugs include capsules and injections. Isotretinoin capsules are oral medications that reduce natural oil production in the skin, prevent clogged pores, and help treat and prevent acne. These drugs are indicated for conditions such as severe acne, neuroblastoma, cutaneous T-cell lymphoma, harlequin ichthyosis, Xeroderma pigmentosum, fibrodysplasia ossificans progressiva, squamous cell skin cancers, and others. They are distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

The isotretinoin drugs market research report is one of a series of new reports that provides isotretinoin drugs market statistics, including isotretinoin drugs industry global market size, regional shares, competitors with an isotretinoin drugs market share, detailed isotretinoin drugs market segments, market trends and opportunities, and any further data you may need to thrive in the isotretinoin drugs industry. This isotretinoin drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The isotretinoin drugs market consists of sales of softgels, tablets, and ointments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.